Qingdao NovelBeam Technology Co Ltd
SSE:688677
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (40.3), the stock would be worth ¥48.5 (52% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 83.5 | ¥100.52 |
0%
|
| 3-Year Average | 40.3 | ¥48.5 |
-52%
|
| 5-Year Average | 40.7 | ¥48.96 |
-51%
|
| Industry Average | 19.5 | ¥23.48 |
-77%
|
| Country Average | 18.3 | ¥21.98 |
-78%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
Q
|
Qingdao NovelBeam Technology Co Ltd
SSE:688677
|
12.1B CNY | 83.5 | 69.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 56.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 16.5 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 24.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 14.7 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 20.3 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 13.2 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 30.6 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 38.2 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 12.8 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.7 | 21.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Qingdao NovelBeam Technology Co Ltd
Glance View
Qingdao NovelBeam Technology Co., Ltd. engages in the research and development of optics technology, the manufacture of optical instruments, and the provision of design solutions for medical, life science, laser, and micro-display projection applications. The company is headquartered in Qingdao, Shandong and currently employs 854 full-time employees. The company went IPO on 2021-02-26. Its main products of medical endoscope equipment include fluorescent endoscopes, fluorescent camera adapters/adaptive lenses, fluorescent light source modules and white light source modules. Its medical endoscopic equipment products are mainly used in abdominal endoscopic surgery such as liver and gallbladder and gastrointestinal surgery. Its optical products mainly include medical optical products, industrial and laser optical products, and biometric products. Among them, the biometric products include fingerprint devices, palmprint devices and related accessories. In addition, the Company also provides technical services and house leasing services. The firm distributes its products both in the domestic market and to overseas markets.
